Answers are grounded in this paper and cite their sources.
A therapeutic trial with methenolone (Primobolan) in 19 consecutive patients with different types of refractory anemia is reported. The remission frequencies were: pancytopenia 3/6, bicytopenia 2/4, refractory anemia with hyperplastic marrow 1/5, myelofibrosis 1/4. There was no obvious prolongation of survival in the patients responding. Side-effects were negligible.
No takes yet. Share an insight, caveat, or question.
D. Lockner (1979) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: